[1]Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis; report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. Q J Med, 1954,23(91):347-366. [2]Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis,2012,16(6):724-732.[3]World Health Orgnization. Treatment for tuberculosis. Guidelines for National Programmes. WHO/TB/97.220. Geneva: World Health Orgnization,1998. [4]World Health Orgnization. Multidrug and extensively drug-resistant TB (M/XDR-TB). 2010 Global report on surveillance and response.WHO/HTM/TB/2010.3.Geneva:World Health Organization, 2010.[5]Nuermberger EL, Spigelman MK, Yew WW.Current development and future prospects in chemotherapy of tuberculosis. Respirology, 2010, 15(5):764-778. [6]吴小林.治疗结核病新药和药物作用靶位. 国外医药(抗生素分册),2007,28(2):70-73.[7]冯连顺,吕凯, 刘明亮. 结核病的潜在治疗策略. 国外医药(抗生素分册),2010, 31(3):123-132.[8]Rosenthal IM, Zhang M, Williams KN,et al. Daily dosing of rifapentine cures tuberculosis in three months or less in murine model. PLoS Med, 2007,4(12):e344.[9]Zhang Y. Advances in the treatment of tuberculosis. Clin Pharmacol Ther,2007,82(5):595-600. |